$5.770
-0.184 (-3.19%)Zum Schluss
TSHA-News
TSHA-Events
Taysha CEO Highlights TSHA-102 Clinical Progress
"During the second quarter, we continued to execute against our clinical development strategy for TSHA-102 while advancing key commercial and manufacturing readiness initiatives in support of a potential BLA submission," said Sean P. Nolan, Chairman and Chief Executive Officer of Taysha. "The completion of dosing in our REVEAL pivotal and ASPIRE trials, as well as positive longer-term follow-up data from our REVEAL Phase 1/2 trials continues to strengthen our conviction in TSHA-102 as a potentially transformative therapy for this devastating disease with high unmet need. In addition, the favorable safety profile observed to date across a broad and diverse patient population supports TSHA-102's potential to safely deliver durable, meaningful functional benefits."
Taysha and Catalent Sign Commercial Supply Agreement for TSHA-102
Taysha Gene Therapies and Catalent announced a commercial supply agreement for TSHA-102, Taysha's investigational gene therapy in pivotal development for Rett syndrome, under which Catalent will serve as Taysha's primary commercial manufacturer following potential FDA approval. The agreement secures long-term commercial manufacturing capacity and a scalable supply framework to support a potential commercial launch and future demand. Catalent will provide GMP manufacturing and commercial supply of TSHA-102 at its FDA-licensed commercial gene therapy facility in Harmans, Maryland, leveraging its experience across more than 90 gene therapy programs, including multiple commercial products.
Taysha Gene Therapies Shares Down 11% to $5.64
Taysha Gene Therapies is down -11.0%, or -70c to $5.64.
Baird Prices Offering Below Last Close of $6.94
The deal priced below last closing price of $6.94. Baird is acting as sole book running manager for the offering.
Micron Technology Shares Rise 14.4%, Boosting Semiconductor Sector
The tech sector remained under pressure on Wednesday as investors continued to flock to the safety of counter-cyclical areas of the market such as Utilities and Health Care. Energy lagged as continued signs of a Middle East de-escalation and progress in Strait of Hormuz reopening has pulled the price of WTI Crude Oil futures below $70 per barrel.The evening session and a blowout earnings report from Micronhas manifested a sea change in sentiment and the likelihood of a snap-back rally in the AI trade on Thursday. Shares of the memory maker were up over 14%, nearly erasing all of yesterday's broadbased losses. The strong results from Micron also put a bid under the other semiconductor and memory names. Elsewhere, a robust medium-term outlook from Qualcommwith a higher non-handset revenue target of $40B further relieved the tensions regarding valuations in Semis. Late in afterhours, S&P e-minis are up 10.6% and Nasdaq 100 contract is up 2.0%.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Micronup 14.4%; Other semis and memory names broadly up in sympathy: Lam Researchup 6.5%, Rambusup 6.8%, Arm Holdingsup 6.7%, Sandiskup 11.1%, Western Digitalup 10.9%.Methode Electronics, Inc.up 14.4%ALSO HIGHER -Qualcommup 12.9% after disclosing medium-term targetsNETSTREITup 5.8% after entering S&P SmallCap 600 indexFormFactor, Inc.up 5.2% after being added to Russell 1000 indexDOWN AFTER EARNINGS -MillerKnolldown 4.9%Trip.com Group Limiteddown 4.3%H.B. Fullerdown 1.9%Jefferiesdown 1.6%ALSO LOWER -ARS Pharmaceuticalsdown 23.8% after commercial update on neffyTaysha Gene Therapiesdown 7.8% after equity offeringCG Oncology, Inc.down 5.4% after block trade
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.